Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trialYuankai Shi, Huaize Geng, Xuezhi Hao et al.|Signal Transduction and Targeted Therapy|2022Cited by 35